Department of Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, B-9820 Merelbeke, Belgium.
Exp Cell Res. 2013 Mar 10;319(5):575-87. doi: 10.1016/j.yexcr.2012.11.013. Epub 2012 Nov 29.
The breast cancer type 1 susceptibility protein (BRCA1) is involved in several important cellular pathways, including DNA damage repair, chromatin remodeling and checkpoint activation. The BRCA1 tumor suppression function has been attributed to its role in homologous recombination damage repair. In this review, historical facts concerning BRCA1, together with recent research advances regarding our understanding of the BRCA1 interacting proteins that are involved in, homologous recombination (HR) double strand break (DBS) repair and how these interacting proteins maintain chromosomal integrity, are discussed. In addition, this review poses the questions as to what extent HR repair cannot be properly fulfilled when breast cancer related mutations in the BRCA1 gene occur and how the recent and excessive studied poly-ADP ribose polymerase (PARP) inhibiting therapy approach links with the proposed tumor suppression function of the different BRCA1 domains.
乳腺癌 1 型易感蛋白(BRCA1)参与了几个重要的细胞途径,包括 DNA 损伤修复、染色质重塑和检查点激活。BRCA1 的肿瘤抑制功能归因于其在同源重组损伤修复中的作用。在这篇综述中,讨论了有关 BRCA1 的历史事实,以及最近关于我们对参与同源重组(HR)双链断裂(DBS)修复的 BRCA1 相互作用蛋白的理解的研究进展,以及这些相互作用蛋白如何维持染色体的完整性。此外,还提出了以下问题:当 BRCA1 基因发生乳腺癌相关突变时,HR 修复在多大程度上不能正常进行,以及最近过度研究的聚 ADP 核糖聚合酶(PARP)抑制治疗方法与不同 BRCA1 结构域提出的肿瘤抑制功能之间的联系。